EXOZYMES INC. Information Technology and Data Processing
EXOZYMES INC. (EXOZ) reported Information Technology and Data Processing of $11.76 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InformationTechnologyAndDataProcessing · last filed 2026-08-13
- EXOZYMES INC. information technology and data processing for the quarter ending 2026-06-30 was $11.76K, a 71.89% decline year-over-year.
- EXOZYMES INC. information technology and data processing for the quarter ending 2026-03-31 was $10.30K, a 59.30% decline year-over-year.
- EXOZYMES INC. information technology and data processing for the quarter ending 2025-12-31 was $20.66K, a 120.02% increase year-over-year.
- EXOZYMES INC. information technology and data processing for the quarter ending 2025-09-30 was $8.18K, a 47.80% decline year-over-year.
- EXOZYMES INC. information technology and data processing for fiscal 2025 was $95.99K, a 148.30% increase from fiscal 2024.
- EXOZYMES INC. information technology and data processing for fiscal 2024 was $38.66K, a 77.31% increase from fiscal 2023.
- EXOZYMES INC. information technology and data processing for fiscal 2023 was $21.80K.
| Period end | Information Technology and Data Processing 3 month | Information Technology and Data Processing 6 month | Information Technology and Data Processing 9 month | Information Technology and Data Processing 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.76K 10-Q · filed 2026-08-13 | $22.06K 10-Q · filed 2026-08-13 | $42.73K derived: sum of 3 quarters · filed 2026-08-13 | $50.90K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $10.30K 10-Q · filed 2026-05-14 | $30.97K derived: sum of 2 quarters · filed 2026-05-14 | $39.14K derived: sum of 3 quarters · filed 2026-05-14 | $80.98K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $20.66K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $28.84K derived: sum of 2 quarters · filed 2026-03-30 | $70.67K derived: sum of 3 quarters · filed 2026-08-13 | $95.99K 10-K · filed 2026-03-30 |
| 2025-09-30 | $8.18K 10-Q · filed 2025-11-13 | $50.01K derived: sum of 2 quarters · filed 2026-08-13 | $75.33K 10-Q · filed 2025-11-13 | $84.72K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $41.84K 10-Q · filed 2026-08-13 | $67.15K 10-Q · filed 2026-08-13 | $76.54K derived: sum of 3 quarters · filed 2026-08-13 | $92.20K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $25.32K 10-Q · filed 2026-05-14 | $34.71K derived: sum of 2 quarters · filed 2026-05-14 | $50.37K derived: sum of 3 quarters · filed 2026-05-14 | $60.08K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $9.39K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $25.05K derived: sum of 2 quarters · filed 2026-03-30 | $34.77K derived: sum of 3 quarters · filed 2026-03-30 | $38.66K 10-K · filed 2026-03-30 |
| 2024-09-30 | $15.66K 10-Q · filed 2025-11-13 | $25.38K derived: sum of 2 quarters · filed 2025-11-13 | $29.27K 10-Q · filed 2025-11-13 | $34.82K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $9.71K 10-Q · filed 2025-08-12 | $13.61K 10-Q · filed 2025-08-12 | $19.16K derived: sum of 3 quarters · filed 2025-08-12 | $26.17K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $3.89K 10-Q · filed 2025-05-12 | $9.45K derived: sum of 2 quarters · filed 2025-05-12 | $16.46K derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | $5.56K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $12.57K derived: sum of 2 quarters · filed 2025-03-31 | $21.80K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $7.01K 10-Q · filed 2024-11-12 | $16.25K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |